Pamela Stephenson
Corporate Officer/Principal chez DISC MEDICINE, INC.
Fortune : 972 382 $ au 30/04/2024
Postes actifs de Pamela Stephenson
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| DISC MEDICINE, INC. | Corporate Officer/Principal | 26/02/2024 | - |
Historique de carrière de Pamela Stephenson
Anciens postes connus de Pamela Stephenson
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Directeur/Membre du Conseil | 19/02/2019 | 10/10/2023 |
| Independent Dir/Board Member | 19/02/2019 | 10/10/2023 | |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/07/2008 | 01/03/2019 |
| ALBIREO PHARMA, INC. | Corporate Officer/Principal | 25/03/2019 | - |
Formation de Pamela Stephenson
| Brown University | Undergraduate Degree |
| Boston University School of Public Health | Graduate Degree |
Statistiques
Internationale
| Etats-Unis | 7 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Director/Board Member | 1 |
| Independent Dir/Board Member | 1 |
Sectorielle
| Health Technology | 5 |
| Consumer Services | 3 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ZYNERBA PHARMACEUTICALS, INC. | Health Technology |
| VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
| DISC MEDICINE, INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Albireo Pharma, Inc.
 Albireo Pharma, Inc. Pharmaceuticals: MajorHealth Technology Albireo Pharma, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of novel bile acid modulators for the treatment of orphan pediatric liver diseases and gastrointestinal disorders. Its pipeline products include Odevixibat, A3384, and Elobixibat. The company was founded by Jan Peter Mattsson and Per-Göran Gillberg on December 8, 2003 and is headquartered in Boston, MA. | Health Technology |
- Bourse
- Insiders
- Pamela Stephenson
- Expérience